AmeriFlex Group’s NanoViricides NNVC Stock Holding History

AmeriFlex Group’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100	Closed	-$117	–	1212
2025 Q1	$117	Hold	100	–	–	﹤0.01%	1257
2024 Q4	$120	Buy	+100	New	+$144	﹤0.01%	1143

Other funds holding NNVC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AmeriFlex Group's NNVC Position: Q2 2025 in Review

AmeriFlex Group sold out of NanoViricides (NNVC) in Q2 2025, closing a stake of 100 shares — an estimated $117 sold.

AmeriFlex Group first reported a position in NNVC in Q4 2024 and held it in 2 quarters. The position peaked at $120 in Q4 2024. 33 funds tracked by Wall St. Rank hold NNVC as of Q2 2025.

AmeriFlex Group reported no remaining NanoViricides position as of Q2 2025 after selling out during the quarter.
AmeriFlex Group sold 100 NanoViricides shares in Q2 2025, an estimated $117.
AmeriFlex Group first reported a position in NanoViricides in Q4 2024 and held it in 2 quarters.
AmeriFlex Group's NanoViricides position peaked at $120 in Q4 2024.
33 funds tracked by Wall St. Rank held NanoViricides as of Q2 2025.

Based on AmeriFlex Group's 13F filing for Q2 2025, filed 21 Jul 2025.